MSC vs HSCT for Rheumatoid Arthritis: what the registries show
For Rheumatoid Arthritis, the registry holds 22 MSC records against 11 HSCT records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | HSCT |
|---|---|---|
| Registered studies | 22 | 11 |
| Recruiting now | 2 | 2 |
| Phase 3 or 4 records | 1 | 1 |
| Completed | 7 | 5 |
| Stopped early | 1 | 2 |
| Countries with sites | 11 | 12 |
| Median planned enrolment | 36 | 24 |
| First registration year | 2,009 | 1,997 |
The condition underneath the comparison
Rheumatoid arthritis is autoimmune synovial inflammation causing joint erosion. Mesenchymal cells are studied for immunomodulation, generally in disease refractory to conventional and biologic therapy. As with psoriasis, effective established treatments define the comparison — the question is not whether cells do something, but whether they beat what already works.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
HSCT: what it is
Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.
Maturity difference
MSC has 1 Phase 3/4 records and 7 completed studies; HSCT has 1 and 5. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06805448 — Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients With Xerostomia Due to Sjögren's Disease | Phase 1, Phase 2 | Recruiting | 40 | Rigshospitalet, Denmark | 2025-01-21 |
| NCT05003934 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA | Phase 1 | Recruiting | 20 | The Foundation for Orthopaedics and Regenerative Medicine | 2021-11-07 |
| NCT04971980 — Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis | Phase 1, Phase 2 | Active Not Recruiting | 9 | Beijing Baylx Biotech Co., Ltd. | 2021-04-12 |
| NCT01873625 — Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis | Phase 2, Phase 3 | Completed | 60 | Royan Institute | 2009-10 |
| NCT07290946 — Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors | Phase 2 | Not Yet Recruiting | 100 | Christian von Buchwald | 2025-12 |
Leading HSCT studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT01962415 — Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | Phase 2 | Recruiting | 100 | Paul Szabolcs | 2014-02-04 |
| NCT04528355 — Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC | n/a | Recruiting | 50 | Paul Szabolcs | 2020-08-20 |
| NCT01873625 — Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis | Phase 2, Phase 3 | Completed | 60 | Royan Institute | 2009-10 |
| NCT02759731 — Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Completed | 24 | National Cancer Institute (NCI) | 2016-11-01 |
| NCT03067870 — Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis | Phase 1 | Unknown | 100 | Stem Cells Arabia | 2016-11 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than HSCT for Rheumatoid Arthritis?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 22 vs 11 registered records (2026-08-29).
Which has more late-stage research for Rheumatoid Arthritis?
MSC: 1 Phase 3/4 records. HSCT: 1.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.